Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Should You Buy?

Company Overview - Axsome Therapeutics (AXSM) is expected to report a year-over-year increase in earnings due to higher revenues for the quarter ended December 2025, with a consensus outlook indicating a quarterly loss of $0.70 per share, representing a 27.1% improvement from the previous year [1][3] - Revenues are anticipated to reach $193.01 million, reflecting a significant increase of 62.5% compared to the same quarter last year [3] Earnings Estimates and Revisions - The consensus EPS estimate has been revised 7.1% higher in the last 30 days, indicating a positive reassessment by analysts regarding the company's earnings prospects [4] - The Most Accurate Estimate for Axsome is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +30.00%, suggesting a strong likelihood of beating the consensus EPS estimate [12] Earnings Surprise History - In the last reported quarter, Axsome was expected to post a loss of $0.82 per share but actually reported a loss of $0.94, resulting in a surprise of -14.63% [13] - Over the past four quarters, the company has successfully beaten consensus EPS estimates three times [14] Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Insmed (INSM) is also expected to report a loss of $1.07 per share for the same quarter, with a year-over-year change of +18.9% and anticipated revenues of $263.87 million, up 152.7% from the previous year [18][19] - Insmed's consensus EPS estimate has been revised 37.1% higher in the last 30 days, resulting in an Earnings ESP of +7.01%, indicating a likelihood of beating the consensus EPS estimate [19][20]